

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/S77749DECA3DEN.html>

Date: December 2022

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: S77749DECA3DEN

Abstracts

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Survival Motor Neuron Protein - Drugs In Development, 2022, outlays comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs). They play an important role in the splicing of cellular pre-mRNAs. They ensure the correct splicing of U12 intron-containing genes that is important for normal motor and proprioceptive neurons development. They are required for resolving RNA-DNA hybrids created by RNA polymerase II. They play a role in the metabolism of small nucleolar ribonucleoprotein. The molecules developed

by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Spinal Muscular Atrophy (SMA) and Huntington Disease.

Furthermore, this report also reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)

The report reviews Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics and enlists all their major and minor projects

The report assesses Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics based on mechanism of

action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) -
Overview

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) -
Companies Involved in Therapeutics Development

Amogen Pharma Pvt Ltd

Beijing GeneCradle Technology Co Ltd

Biocad

CANbridge Life Sciences Ltd

F. Hoffmann-La Roche Ltd

Huida (Shanghai) Biotechnology Co Ltd

Novartis AG

Novartis Gene Therapies

Sarepta Therapeutics Inc

Shift Pharmaceuticals

Spotlight Innovation Inc (Inactive)

Suzhou GenAssist Therapeutics Co Ltd

Voyager Therapeutics Inc

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) -
Drug Profiles

ALB-111 - Drug Profile

Product Description

Mechanism Of Action

ANB-4 - Drug Profile

Product Description

Mechanism Of Action

Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

History of Events

branaplam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

E-1V111 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GC-101 - Drug Profile

Product Description

Mechanism Of Action

GEN-8010 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

HG-001 - Drug Profile

Product Description

Mechanism Of Action

onasemnogene abeparvovec - Drug Profile

Product Description

Mechanism Of Action

History of Events

onasemnogene abeparvovec - Drug Profile

Product Description

Mechanism Of Action

PMO-25 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Resagen - Drug Profile

Product Description

Mechanism Of Action

History of Events

risdiplam - Drug Profile

Product Description

Mechanism Of Action

History of Events

Second-Generation scAAV9 Gene Therapy - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules 2 to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

STL-182 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Survival Motor Neuron Protein (Component Of Gemin 1 or Gemin 1 or SMN1 or SMN2) -
Dormant Products

Survival Motor Neuron Protein (Component Of Gemin 1 or Gemin 1 or SMN1 or SMN2) -
Discontinued Products

Survival Motor Neuron Protein (Component Of Gemin 1 or Gemin 1 or SMN1 or SMN2) -
Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Amogen Pharma Pvt Ltd, 2022

Pipeline by Beijing GeneCradle Technology Co Ltd, 2022

Pipeline by Biocad, 2022

Pipeline by CANbridge Life Sciences Ltd, 2022

Pipeline by F. Hoffmann-La Roche Ltd, 2022

Pipeline by Huida (Shanghai) Biotechnology Co Ltd, 2022

Pipeline by Novartis AG, 2022

Pipeline by Novartis Gene Therapies, 2022

Pipeline by Sarepta Therapeutics Inc, 2022

Pipeline by Shift Pharmaceuticals, 2022

Pipeline by Spotlight Innovation Inc (Inactive), 2022

Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022

Pipeline by Voyager Therapeutics Inc, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2)
Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players,
2022 Update

Product link: <https://marketpublishers.com/r/S77749DECA3DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/S77749DECA3DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970